Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants
- PMID: 25653499
- PMCID: PMC4307650
- DOI: 10.2147/DDDT.S62912
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants
Abstract
Evidence suggesting that central nervous system γ-aminobutyric acid (GABA) concentrations are reduced in patients with major depressive disorder (MDD) has been present since at least 1980, and this idea has recently gained support from more recent magnetic resonance spectroscopy data. These observations have led to the assumption that MDD's underlying etiology is tied to an overall reduction in GABA-mediated inhibitory neurotransmission. In this paper, we review the mechanisms that govern GABA and glutamate concentrations in the brain, and provide a comprehensive and critical evaluation of the clinical data supporting reduced GABA neurotransmission in MDD. This review includes an evaluation of magnetic resonance spectroscopy data, as well as data on the expression and function of the GABA-synthesizing enzyme glutamic acid decarboxylase, GABA neuron-specific cell markers, such as parvalbumin, calretinin and calbindin, and the GABAA and GABAB receptors in clinical MDD populations. We explore a potential role for glial pathology in MDD-related reductions in GABA concentrations, and evidence of a connection between neurosteroids, GABA neurotransmission, and hormone-related mood disorders. Additionally, we investigate the effects of GABAergic pharmacological agents on mood, and demonstrate that these compounds have complex effects that do not universally support the idea that reduced GABA neurotransmission is at the root of MDD. Finally, we discuss the connections between serotonergic and GABAergic neurotransmission, and show that two serotonin-focused antidepressants - the selective serotonin-reuptake inhibitor fluoxetine and the multimodal antidepressant vortioxetine - modulate GABA neurotransmission in opposing ways, despite both being effective MDD treatments. Altogether, this review demonstrates that there are large gaps in our understanding of the relationship between GABA physiology and MDD, which must be remedied with more data from well-controlled empirical studies. In conclusion, this review suggests that the simplistic notion that MDD is caused by reduced GABA neurotransmission must be discarded in favor of a more nuanced and complex model of the role of inhibitory neurotransmission in MDD.
Keywords: 5-HT; GABA; major depressive disorder; serotonin.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4307650/bin/dddt-9-603Fig1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4307650/bin/dddt-9-603Fig2.gif)
Similar articles
-
Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.CNS Spectr. 2016 Apr;21(2):162-83. doi: 10.1017/S1092852915000486. Epub 2015 Aug 7. CNS Spectr. 2016. PMID: 26250622 Review.
-
Modulating the serotonin system in the treatment of major depressive disorder.CNS Spectr. 2014 Dec;19 Suppl 1:57-67; quiz 54-7, 68. doi: 10.1017/S1092852914000613. CNS Spectr. 2014. PMID: 25544378 Review.
-
Vortioxetine: a New Treatment for Major Depressive Disorder.Expert Opin Pharmacother. 2016;17(3):421-31. doi: 10.1517/14656566.2016.1133588. Expert Opin Pharmacother. 2016. PMID: 26679430 Review.
-
A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.Psychopharmacology (Berl). 2016 Sep;233(17):3259-67. doi: 10.1007/s00213-016-4364-0. Epub 2016 Jun 29. Psychopharmacology (Berl). 2016. PMID: 27356518
-
Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.CNS Neurol Disord Drug Targets. 2017;16(1):65-92. doi: 10.2174/1871527315666161025140111. CNS Neurol Disord Drug Targets. 2017. PMID: 27781949 Review.
Cited by
-
Fermented foods, their microbiome and its potential in boosting human health.Microb Biotechnol. 2024 Feb;17(2):e14428. doi: 10.1111/1751-7915.14428. Microb Biotechnol. 2024. PMID: 38393607 Free PMC article. Review.
-
Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders.Chronic Stress (Thousand Oaks). 2024 Jan 17;8:24705470231225320. doi: 10.1177/24705470231225320. eCollection 2024 Jan-Dec. Chronic Stress (Thousand Oaks). 2024. PMID: 38250007 Free PMC article.
-
Neuroplasticity of the left dorsolateral prefrontal cortex in patients with treatment-resistant depression as indexed with paired associative stimulation: a TMS-EEG study.Cereb Cortex. 2024 Jan 31;34(2):bhad515. doi: 10.1093/cercor/bhad515. Cereb Cortex. 2024. PMID: 38204301 Free PMC article.
-
GABAA Receptor Availability in Relation to Cortical Excitability in Depressed and Healthy: A Positron Emission Tomography and Transcranial Magnetic Stimulation Study.Neuropsychobiology. 2024;83(1):17-27. doi: 10.1159/000535512. Epub 2023 Dec 27. Neuropsychobiology. 2024. PMID: 38151012 Free PMC article.
-
Transcriptional changes in the rat brain induced by repetitive transcranial magnetic stimulation.Front Hum Neurosci. 2023 Nov 13;17:1215291. doi: 10.3389/fnhum.2023.1215291. eCollection 2023. Front Hum Neurosci. 2023. PMID: 38021223 Free PMC article.
References
-
- World Health Organization Depression. 2012. [Accessed September 11, 2014]. Available from: http://www.who.int/mediacentre/factsheets/fs369/en.
-
- McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527. - PubMed
-
- Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78–89. - PubMed
-
- Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48. - PubMed
-
- Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(Suppl 14):11–14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical